These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 20865636

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Complement in typical hemolytic uremic syndrome.
    Orth D, Würzner R.
    Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI.
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [Abstract] [Full Text] [Related]

  • 6. Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.
    Cornick NA, Jelacic S, Ciol MA, Tarr PI.
    J Infect Dis; 2002 Jul 01; 186(1):57-63. PubMed ID: 12089662
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
    Ito K, Hattori M, Matsumoto N.
    Nihon Rinsho; 2002 Jun 01; 60(6):1126-30. PubMed ID: 12078084
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Conserved Stx2 phages from Escherichia coli O103:H25 isolated from patients suffering from hemolytic uremic syndrome.
    Sekse C, Muniesa M, Wasteson Y.
    Foodborne Pathog Dis; 2008 Dec 01; 5(6):801-10. PubMed ID: 19014273
    [Abstract] [Full Text] [Related]

  • 11. Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome similar to septic shock.
    Valles PG, Pesle S, Piovano L, Davila E, Peralta M, Principi I, Lo Giudice P.
    Medicina (B Aires); 2005 Dec 01; 65(5):395-401. PubMed ID: 16296634
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Hemolytic uremic syndrome caused by Shiga-toxin-producing Escherichia coli].
    Loirat C.
    Rev Prat; 2013 Jan 01; 63(1):11-6. PubMed ID: 23457821
    [Abstract] [Full Text] [Related]

  • 16. Escherichia coli Shiga toxin.
    Nakao H, Takeda T.
    J Nat Toxins; 2000 Aug 01; 9(3):299-313. PubMed ID: 10994531
    [Abstract] [Full Text] [Related]

  • 17. [Hemolytic uremic syndrome].
    Rota S, Cravedi P, Remuzzi G, Ruggenenti P.
    G Ital Nefrol; 2005 Aug 01; 22 Suppl 33():S57-64. PubMed ID: 16419008
    [Abstract] [Full Text] [Related]

  • 18. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C.
    J Immunol; 2011 Jul 01; 187(1):172-80. PubMed ID: 21642543
    [Abstract] [Full Text] [Related]

  • 19. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
    Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R.
    J Immunol; 2009 May 15; 182(10):6394-400. PubMed ID: 19414792
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.